财通证券资管旗下3只基金增聘王鑫园

Core Insights - The announcement from Caitong Securities indicates the appointment of Wang Xinyuan as a new fund manager for three of its mutual funds, reflecting a strategic move to enhance management capabilities in the healthcare and pharmaceutical sectors [1][2]. Fund Performance Summary - Caitong Asset Management Healthcare Mixed Fund A/C: - Year-to-date return: 26.53% (A), 26.09% (C) - Since inception return: 12.16% (A), 11.14% (C) - Cumulative net value: 1.1216 (A), 1.1114 (C) [1] - Caitong Asset Management Innovative Pharmaceutical Mixed Fund A/C: - Year-to-date return: 52.66% (A), 52.13% (C) - Since inception return: 49.13% (A), 48.04% (C) - Cumulative net value: 1.4913 (A), 1.4804 (C) [1] - Caitong Asset Management Health Industry Mixed Fund A/C: - Year-to-date return: 27.87% (A), 27.43% (C) - Since inception return: 12.37% (A), 10.61% (C) - Cumulative net value: 1.1237 (A), 1.1061 (C) [1] Fund Manager Details - Wang Xinyuan has been appointed as the new fund manager for the three funds, previously working at Northeast Securities and joining Caitong Securities in March 2019 [1][2]. - Wang Xinyuan will be co-managing the funds alongside Yi Xiaojin [2].